Acute Leukemia: An Illustrated Guide to Diagnosis and Treatment

Acute Leukemia: An Illustrated Guide to Diagnosis and Treatment provides a comprehensive and concise visual reference on acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) seen in children and adults. This book addresses all aspects of AML and ALL including their risk factors, cytogenetics and mutational characteristics, diagnoses, clinical management and prognoses which are imperative and challenging for medical students, residents, hematology and medical oncology fellows, and even community oncologists and hematologists. It presents complex information relying predominantly on pictorial depictions rather than traditional text in a visually instructive format. It replaces the wordiness of a traditional textbook with original and adapted illustrations, instructive schemata and diagrams, photomicrographs, tables, detailed figure legends, and practical, 'bite-sized' text. The result is a visually engaging book that is easy to read, review, and remember. Crafted by world experts in the field, this digestible volume provides you with the must-know information that you can utilize when encountering AML and ALL patients who require immediate attention. Whether you are an early-career practitioner looking for quick guidance to managing a deadly disease or you are a seasoned clinician looking for a quick review of treatment protocols, this engaging format provides a unique and 'go-to' resource. Key Features:* Contains over 40 tables and over 220 illustrations, histologic photomicrographs, flow diagrams, graphs, and schemata with detailed figure legends* Presents complex scientific aspects such as cytogenetics and molecular mutations in a visually digestible and easy-to-understand format* Provides helpful and evidence-based treatment recommendations when providing induction therapy, consolidation therapy, and bone marrow transplantation* Includes unique chapters on managing psychosexual issues accompanying AML and ALL treatment as well as on the FDA drug development and clinical trial design process* Includes digital access to the e-book as well as an online Image Bank

Table of Contents:
Contents Contributors Abbreviations Preface 1. Epidemiology Ashkan Emadi, Farin Kamangar, and Judith E. Karp 2. Diagnosis Clinical Manifestations of Acute Leukemia Daniel L. Duncan, Nathan D. Montgomery, Matthew C. Foster, and Joshua F. Zeidner Pathology, Classification, and Methodologies Histopathology Zeba N. Singh and Qing C. Chen Classification of AML Zeba N. Singh and Qing C. Chen Classification of ALL Zeba N. Singh and Qing C. Chen Classical Genetics Ying Zou and Yi Ning Modern Molecular Genetics Parvez M. Lokhandwala and Christopher D. Gocke Molecular Mutations in AML Catherine Lai FLT3 Mark J. Levis C-KIT Joshua F. Zeidner Ras/Raf/MEK/ERK Pathways Frank McCormick NPM1 Alexander E. Perl PI3K/AKT/mTOR Pathway Mohamed Rahmani and Steven Grant RUNX1 Chandrima Sinha, Lea C. Cunningham, and Paul P. Liu MLL Peter D. Aplan CEBPa Alan D. Friedman GATA2 Dennis D. Hickstein DNMT3A Timothy J. Ley and David H. Spencer TET and IDH Amir T. Fathi WT1 Sheenu Sheela, John Barrett, and Catherine Lai ASXL1 and EZH2 Lizamarie Bachier-Rodriguez and Joseph M. Scandura EVI1 Ling Li and Guido Marcucci p53 Sami N. Malek Secondary AML (s-AML) R. Coleman Lindsley MicroRNAs: Networks in Acute Leukemia Lukasz P. Gondek and Gabriel Ghiaur Prognostic Implication of Mutational Interplay Ashkan Emadi and Judith E. Karp Molecular Mutations in ALL Kristen O’Dwyer and Anjali Advani 3. Therapy Management of Early Crisis Hyperleukocytosis Heather J. Male and Tara Lin Tumor Lysis and Cytokine Release Syndromes Ashkan Emadi and Judith E. Karp Febrile Neutropenia Judith E. Karp Treatment of AML in Adults AML Treatment in Younger Patients Joshua F. Zeidner and Matthew C. Foster AML Treatment in Older Patients Houman Nourkeyhani and Eunice S. Wang Treatment of Relapsed/Refractory AML Mark R. Litzow and Selina M. Luger Acute Promyelocytic Leukemia (APL) Aziz Nazha, Steven D. Gore, and Amer Methqal Zeidan MDS/AML Fundamentals of Epigenetics Monica Reddy Muppidi, Priyank P. Patel, Adam R. Karpf, and Elizabeth A. Griffiths Clonal Evolution and Treatment of Secondary AML and MDS/AML Vu H. Duong and Amer Methqal Zeidan Treatment of ALL in Adults Matthew J. Wieduwilt Risk Stratification General Therapeutic Principles Relapsed/Refractory ALL Conclusion Treatment of AML in Children/Adolescents Jessica Knight-Perry and Lia Gore De Novo AML APML AML With Trisomy 21 Relapsed/Refractory AML Common Complications and Supportive Care Indication for Allogeneic Stem Cell Transplant Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma: Epidemiology, Survival Trends, and Optimal Therapy Archie Bleyer Treatment of ALL in Children and Adolescents Susan R. Rheingold and Stephen P. Hunger Prognostic Indicators/Risk Stratification ALL Therapy Radiation Therapy Outcome Infant ALL Down Syndrome-Associated ALL Philadelphia Chromosome Positive (Ph+) and Philadelphia Chromosome-Like ALL Targeted Therapies Relapsed/Refractory ALL Indications for Allogeneic Stem Cell Transplant 4. Allogeneic Transplant in Adults and Children for AML and ALL Allen R. Chen, Gordon Cohen, Sawa Ito, Heather Symons, and Nancy M. Hardy 5. Measurable (Minimal) Residual Disease The Mechanics of Quantized Hematopoiesis Michael R. Loken Fundamentals of Quantitative Antigen Expression Maturation in Hematopoiesis is Characterized by Quantized Steps Neoplastic Transformation Results in Disruption of Maturation Summary Minimal Residual Disease (MRD) in Acute Lymphoblastic Leukemia (ALL): An Important Prognostic Indicator and Efficacy/Response Biomarker in Children and Adults Gregory H. Reaman and Franklin O. Smith III Clinical Significance of MRD Detection Role of MRD as a Drug Development Tool in ALL Sequence-Specific MRD for ALL Aaron C. Logan Measurable Residual Disease for AML Christopher S. Hourigan and Aaron C. Logan 6. Psychosexual Aspects of Management of Acute Leukemia Nancy Corbitt and Trisha Kendall 7. Chemotherapeutic Agents for Treatment of AML and ALL Ashkan Emadi, Noa G. Holtzman, Matthew J. Wieduwilt, and Judith E. Karp 8. New Therapeutic Targets for Acute Leukemia Stem Cells Craig T. Jordan and Daniel A. Pollyea Exploiting the DNA Damage Response and Repair Pathways Ivana Gojo, Keith W. Pratz, and Judith E. Karp Poly(ADP-Ribose) Polymerase (PARP): An Intriguing Molecular Target for Leukemia Targeting Tumor Metabolism for Treatment of Acute Leukemia Firas El Chaer and Ashkan Emadi Mechanisms of Drug Resistance in Acute Leukemia Maria R. Baer Microenvironment Gabriel Ghiaur and Pamela S. Becker Immunology Hanna A. Knaus, Raúl Montiel Esparza, and Ivana Gojo 9. Regulatory Considerations for the Practitioner Donna Przepiorka and Ann T. Farrell Index

About the Author :
Ashkan Emadi, MD, PhD is Professor of Medicine and Pharmacology, Associate Director of Clinical Research at the Marlene and Stewart Greenbaum Comprehensive Cancer, and Director of the Translational Genomics Laboratory at the University of Maryland School of Medicine in Baltimore, Maryland. Judith E. Karp, MD is Professor Emerita of Oncology and Medicine at Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, in Baltimore, Maryland.